ILC2s在肿瘤免疫调控中的研究进展

doi:10.11904/j.issn.1002-3070.2022.06.014

摘要/Abstract

摘要： Ⅱ型固有淋巴细胞(Type 2 innate lymphoid cells,ILC2s)是一类独特的免疫效应细胞,在抗感染、调控炎症和维持免疫稳态中起着重要作用。近期研究表明ILC2s也参与调节肿瘤免疫,在肿瘤微环境中发现了ILC2s,但是目前ILC2s在肿瘤免疫反应和免疫治疗中的作用尚未阐明。有研究表明白细胞介素33(IL-33)可以激活肿瘤微环境中的ILC2s,ILC2s表达抑制性检查点受体PD-1,PD-1阻断剂直接作用于ILC2s,减轻ILC2s细胞固有的PD-1抑制,最终增加了肿瘤组织CD8⁺细胞毒性T淋巴细胞(Cytotoxic T lymphocyte,CTL)浸润,增强了肿瘤免疫反应,活化的肿瘤ILC2s可以作为抗PD-1免疫疗法的靶标。本文就目前ILC2s参与调控肿瘤免疫可能的机制,探讨新的肿瘤免疫检查点抑制剂靶点进行综述。

关键词: Ⅱ型固有淋巴细胞, 肿瘤微环境, 肿瘤免疫

Abstract: Type 2 innate lymphoid cells(ILC2s)are a kind of unique immune effectors’ cells,which play an important role in anti-infection,regulating inflammation and maintaining immune homeostasis.Recent studies have shown that ILC2s are also involved in the regulation of tumor immunity,and ILC2s have been found in the tumor microenvironment.However,the role of ILC2s in tumor immune response and immunotherapy has not been clarified.Studies have shown that ILC2s expression immune checkpoints,interleukin-33(IL-33)can activate ILC2s in the tumor microenvironment,and the inhibitory checkpoint receptor PD-1 of ILC2s expression,PD-1 blockers directly act on ILC2s,reduce the inherent PD-1 inhibition of ILC2s cells,finally increase the infiltration of CD8⁺ cytotoxic T lymphocytes(CTL)in tumor tissues,and enhances the tumor immune response.The activated tumor ILC2s can be used as the target of anti-PD-1 immunotherapy.This review will discuss the possible mechanisms of ILC2s involved in the regulation of tumor immunity and explore new targets of tumor immune checkpoint inhibitors.

Key words: Type 2 innate lymphoid cells, Tumor microenvironment, Tumor immunity

中图分类号:

张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.

ZHANG Shumin, ZHANG Gong. Research progress of ILC2s in tumor immune regulation[J]. Journal of Practical Oncology, 2022, 36(6): 566-569.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/566

参考文献

1 Kabata H,Moro K,Koyasu S.The group 2 innate lymphoid cell(ILC2)regulatory network and its underlying mechanisms[J].Immunol Rev,2018,286(1):37-52.
2 Trabanelli S,Chevalier MF,Derré L,et al.The pro-and anti-tumor role of ILC2s[J].Semin Immunol,2019,41:101276.
3 Ercolano G,Falquet M,Vanoni G,et al.ILC2s:new actors in tumor immunity[J].Front Immunol,2019,10:2801.
4 Bruchard M,Ghiringhelli F.Deciphering the roles of innate lymphoid cells in cancer[J].Front Immunol,2019,10:656.
5 Moral JA,Leung J,Rojas LA,et al.ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity[J].Nature,2020,579(7797):130-135.
6 Hurst SD,Muchamuel T,Gorman DM,et al.New IL-17 family members promote Th1 or Th2 responses in the lung:in vivo function of the novel cytokine IL-25[J].J Immunol,2002,169(1):443-453.
7 von Moltke J,O'Leary CE,Barrett NA,et al.Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s[J].J Exp Med,2017,214(1):27-37.
8 Neill DR,Wong SH,Bellosi A,et al.Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity[J].Nature,2010,464(7293):1367-1370.
9 Wan J,Cai W,Wang H,et al.Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity[J].J Cell Physiol,2020,235(4):3249-3257.
10 Mjsberg J,Bernink J,Golebski K,et al.The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells[J].Immunity,2012,37(4):649-659.
11 Boberg E,Johansson K,Malmh ll C,et al.House dust mite induces bone marrow IL-33-responsive ILC2s and T(H)cells[J].Int J Mol Sci,2020,21(11):3751.
12 McHedlidze T,Waldner M,Zopf S,et al.Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis[J].Immunity,2013,39(2):357-371.
13 Jiang W,Lian J,Yue Y,et al.IL-33/ST2 as a potential target for tumor immunotherapy[J].Eur J Immunol,2021,51(8):1943-1955.
14 Sivori S,Pende D,Quatrini L,et al.NK cells and ILCs in tumor immunotherapy[J].Mol Aspects Med,2021,80:100870.
15 Wang S,Wu P,Chen Y,et al.Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor[J].Oncol Lett,2020,20(2):1513-1525.
16 Xiong J,Wang H,He J,et al.Functions of group 2 innate lymphoid cells in tumor microenvironment[J].Front Immunol,2019,10:1615.
17 Carrega P,Campana S,Bonaccorsi I,et al.The Yin and Yang of innate lymphoid cells in cancer[J].Immunol Lett,2016,179:29-35.
18 Salome B,Jandus C.Innate lymphoid cells in antitumor immunity[J].J Leukoc Biol,2018,103:479-483.
19 Cai H,Wang J,Mo Y,et al.Salidroside suppresses group 2 innate lymphoid cell-mediated allergic airway inflammation by targeting IL-33/ST2 axis[J].Int Immunopharmacol,2020,81:106243.
20 Long A,Dominguez D,Qin L,et al.Type 2 innate lymphoid cells impede IL-33–mediated tumor suppression[J].J Immunol,2018,201:3456-3464.
21 Palucka AK,Coussens LM.The basis of oncoimmunology[J].Cell,2016,164(6):1233-1247.
22 Wan J,Wu Y,Huang L,et al.ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8⁺T cells[J].Cancer Lett,2021,502:34-43.
23 He H,Shi L,Meng D,et al.PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner[J].Cancer Treat Res Commun,2021,28:100379.
24 Villarreal DO,Weiner DB.Interleukin 33:a switch-hitting cytokine[J].Curr Opin Immunol,2014,28(28C):102-106.
25 Jovanovic IP,Pejnovic NN,Radosavljevic GD,et al.Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells[J].Int J Cancer,2014,134(7):1669-1682.
26 Kim J,Kim W,Moon UJ,et al.Intratumorally establishing type 2 innate lymphoid cells blocks tumor growth[J].J Immunol,2016,196(5):2410-2423.
27 Oyesola OO,Duque C,Huang LC,et al.The prostaglandin D(2)receptor CRTH2 promotes IL-33-induced ILC2 accumulation in the lung[J].J Immunol,2020,204(4):1001-1011.
28 Halim TY,Steer CA,Math L,et al.Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation[J].Immunity,2014,40(3):425-435.
29 De Guillebon E,Dardenne A,Saldmann A,et al.Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination[J].Int J Cancer,2020(5),147(6):1509-1518.
30 Topalian SL,Taube JM,Pardoll DM.Neoadjuvant checkpoint blockade for cancer immunotherapy[J].Science,2020,367(6477):eaax0182.
31 Yuan X,Rasul F,Nashan B,et al.Innate lymphoid cells and cancer:role in tumor progression and inhibition[J].Eur J Immunol,2021,51(9):2188-2205.
32 Qiu J,Zhang J,Ji Y,et al.Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity[J].Mucosal Immunology,2021,14(6):1306-1322.
33 Queirolo P,Spagnolo F.Atypical responses in patients with advanced melanoma,lung cancer,renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs:a systematic review[J].Cancer Treat Rev,2017,59:71-78.
34 Pardoll,Drew M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
35 Howard E,Hurrell BP,Helou DG,et al.PD-1 blockade on tumor microenvironment-resident ILC2s promotes TNF-a production and restricts progression of metastatic melanoma[J].Front Immunol,2021,12:733136.
36 Salimi M,Wang R,Yao X,et al.Activated innate lymphoid cell populations accumulate in human tumour tissues[J].BMC Cancer,2018,18(1):341.
37 Miyamoto C,Kojo S,Yamashita M,et al.Runx/Cbfβ complexes protect group 2 innate lymphoid cells from exhausted-like hyporesponsiveness during allergic airway inflammation[J].Nat Commun,2019,10(1):1-13.
38 Saranchova I,Han J,Zaman R,et al.Type 2 innate lymphocytes actuate immunity against tumours and limit cancer metastasis[J].Rep,2018,8(1):2924.

[1]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[2]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[3]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[4]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[5]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[6]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[7]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[8]	牟冠男, 马强. NK细胞极化在子宫内膜癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 534-537.
[9]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[10]	隆园辉, 陈雪松. 心理应激对肿瘤微环境中免疫细胞影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 436-440.
[11]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[12]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[13]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[14]	吕强, 陈洪生, 李国东, 魏九峰(综述), 刘明(审校). 肿瘤相关成纤维细胞在大肠癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 275-279.
[15]	张培, 曹守波, 于雁. 自噬介导的肿瘤相关巨噬细胞调控机制的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 130-134.